The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
This is a 3-part study. Parts 1 and 2 will be a single and multiple ascending dose design, respectively, assessing the safety, tolerability, and PK of ATTO-3712 in healthy adult volunteers. Part 3 will consist of multiple doses in adult patients with atopic dermatitis to assess safety, tolerability, PK, and PD based on biomarkers in the blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
72
Altasciences
Montreal, Quebec, Canada
RECRUITINGIncidence of AEs
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 28.0 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of laboratory abnormalities
Clinical laboratory parameters (hematologic and blood chemistry) will be summarized by visit
Time frame: 0-113 Days for SAD; 0-143 days for MAD
Incidence of ECG abnormalities
ECG findings (including QT abnormalities) will be summarized by visit.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of vital sign abnormalities
Vital signs (systolic and diastolic blood pressure, temperature, heart rate) will be summarized by visit.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Incidence of Anti-Drug Antibodies
Baseline prevelance of ADA, changes in ADA status from prior to the first dose of IP to each applicable post-dose timepoint and ADA titer values for samples confirmed positive for ADA will be evaluated to assess the immunogenicity of single and multiple dose levels of ATT-3712.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Peak plasma concentration (Cmax) ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include maximum concentration (Cmax) of ATTO-3712
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Circulating half-life of ATTO-3712 (t1/2)
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include half-life (t1/2) of ATTO-3712.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Area Under the Plasma Concentration Versus Time Curve (AUC)
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include area under the plasma concentration-time curve (AUC).
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Clearance Rate (C) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the clearance rate (C) of ATTO-3712.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Volume of Distribution (V) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the Volume of distribution (V) of ATTO-3712.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
Bioavailability (F) of ATTO-3712
The pharmacokinetics of single and multiple dose levels of ATTO-3712 in participants will include characterization of the Bioavailability (F) of ATTO-3712.
Time frame: 0-113 Days for SAD; 0-143 Days for MAD
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.